Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review
Autor: | Da-Ming Kong, Wen-Jun Chen, Liang Li |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Male
Oncology Abiraterone Acetate 030232 urology & nephrology ECOG Performance Status Docetaxel urologic and male genital diseases lcsh:RC870-923 Severity of Illness Index chemistry.chemical_compound Prostate cancer 0302 clinical medicine castration-resistant prostate cancer 030219 obstetrics & reproductive medicine Hazard ratio eastern cooperative oncology group performance status gleason score meta-analysis overall survival Abiraterone acetate General Medicine Prognosis Eastern Cooperative Oncology Group performance status Survival Rate Prostatic Neoplasms Castration-Resistant Cabazitaxel Benzamides Taxoids Original Article Radium medicine.drug medicine.medical_specialty Urology Antineoplastic Agents 03 medical and health sciences Internal medicine Nitriles Phenylthiohydantoin medicine Humans Gleason score neoplasms Proportional Hazards Models Taxane Performance status Tissue Extracts business.industry medicine.disease lcsh:Diseases of the genitourinary system. Urology chemistry Neoplasm Grading business |
Zdroj: | Asian Journal of Andrology, Vol 23, Iss 2, Pp 163-169 (2021) Asian Journal of Andrology |
ISSN: | 1745-7262 |
Popis: | Eastern Cooperative Oncology Group (ECOG) performance status and Gleason score are commonly investigated factors for overall survival (OS) in men with castration-resistant prostate cancer (CRPC). However, there is a lack of consistency regarding their prognostic or predictive value for OS. Therefore, we performed this meta-analysis to assess the associations of ECOG performance status and Gleason score with OS in CRPC patients and compare the two markers in patients under different treatment regimens or with different chemotherapy histories. A systematic literature review of monotherapy studies in CRPC patients was conducted in the PubMed database until May 2019. The data from 8247 patients in 34 studies, including clinical trials and real-world data, were included in our meta-analysis. Of these, twenty studies reported multivariate results and were included in our main analysis. CRPC patients with higher ECOG performance statuses (≥ 2) had a significantly increased mortality risk than those with lower ECOG performance statuses ( |
Databáze: | OpenAIRE |
Externí odkaz: |